# PYGM

## Overview
The PYGM gene encodes the muscle-specific isoform of glycogen phosphorylase, a key enzyme involved in glycogenolysis, the metabolic pathway responsible for breaking down glycogen into glucose-1-phosphate. This enzyme plays a critical role in energy metabolism, particularly in muscle tissues, by providing a rapid source of glucose during periods of high energy demand, such as muscle contraction. Glycogen phosphorylase, muscle associated, is categorized as a phosphorylase enzyme, which is regulated through allosteric interactions and reversible phosphorylation, allowing it to respond dynamically to cellular energy needs (MigockaPatrzałek2021Muscle; Echaniz‐Laguna2020A). Mutations in the PYGM gene are linked to McArdle disease, a glycogen storage disorder characterized by exercise intolerance and muscle pain, underscoring the gene's clinical significance (Quinlivan2010McArdle; Santalla2017Genotypic).

## Structure
The PYGM gene encodes the muscle isoform of glycogen phosphorylase, an enzyme essential for glycogen breakdown. The primary structure of the PYGM protein consists of a polypeptide chain of amino acids. Its secondary structure includes alpha-helices and beta-sheets, contributing to its stability and function. The tertiary structure forms a compact, globular shape, which is crucial for its enzymatic activity. In terms of quaternary structure, PYGM can form homodimers or homotetramers, which are important for its functional state in muscle cells.

The protein contains key domains, including catalytic and regulatory sites, which are essential for its role in glycogenolysis. These domains facilitate the enzyme's interaction with other proteins and its regulation by various factors. Common post-translational modifications of PYGM include phosphorylation, which plays a significant role in regulating its activity. Phosphorylation can activate or inhibit the enzyme, depending on the cellular context and the presence of specific signaling molecules (MigockaPatrzałek2021Muscle).

The structural features of PYGM, including its domains and post-translational modifications, are critical for its function in muscle energy metabolism and its involvement in conditions such as McArdle disease (MigockaPatrzałek2021Muscle).

## Function
The PYGM gene encodes the muscle isoform of glycogen phosphorylase, an enzyme crucial for glycogenolysis, the process of breaking down glycogen into glucose-1-phosphate. This enzymatic activity is essential for providing energy during muscle contraction, particularly under conditions of increased energy demand (MigockaPatrzałek2021Muscle; Echaniz‐Laguna2020A). In healthy human cells, PYGM is primarily active in the cytoplasm of muscle cells, where it plays a vital role in maintaining energy homeostasis during physical activity (MigockaPatrzałek2021Muscle).

PYGM is involved in several metabolic pathways, including insulin and glucagon signaling, and is regulated through reversible phosphorylation and allosteric changes. Activators such as AMP enhance its activity, while inhibitors like ATP modulate its function, allowing for efficient glycogen breakdown and energy release (MigockaPatrzałek2021Muscle; Echaniz‐Laguna2020A). The enzyme's activity is crucial for ATP production from glycogen deposits, supporting muscle contraction and other cellular processes (MigockaPatrzałek2021Muscle).

Beyond its role in muscle tissue, PYGM is expressed in various other tissues, including the brain and lymphoid tissues, suggesting additional functions related to its biochemical properties (MigockaPatrzałek2021Muscle). The widespread expression and involvement in multiple pathways highlight its importance in maintaining normal cellular functions and energy metabolism (MigockaPatrzałek2021Muscle).

## Clinical Significance
Mutations in the PYGM gene, which encodes the muscle-specific isoform of glycogen phosphorylase, lead to McArdle disease, also known as glycogen storage disease type V (GSD V). This autosomal recessive disorder is characterized by exercise intolerance, muscle cramps, myalgia, and myoglobinuria due to the inability to break down glycogen in skeletal muscles (Quinlivan2010McArdle; VillarrealSalazar2021Preclinical; Santalla2017Genotypic). The most common mutation associated with McArdle disease is p.R50X, although over 206 pathogenic mutations have been identified, including p.G205S and p.W798R (VillarrealSalazar2021Preclinical; Santalla2017Genotypic).

Patients with McArdle disease often experience a 'second wind' phenomenon, where symptoms improve after a period of exercise due to a switch to alternative fuel substrates for aerobic metabolism (Quinlivan2010McArdle; Santalla2017Genotypic). The severity of the disease varies significantly among individuals, and there is no direct correlation between specific mutations and clinical severity, suggesting the involvement of other genetic and lifestyle factors (Quinlivan2010McArdle). Diagnosis is confirmed through DNA analysis or muscle biopsy, and management includes lifestyle modifications to avoid strenuous exercise and maintain hydration (Mamidi2019Pigment).

## Interactions
The PYGM gene encodes muscle glycogen phosphorylase, which is involved in various protein and nucleic acid interactions. PYGM interacts with several proteins crucial for glycogen metabolism, including phosphorylase b kinase (PHK), calmodulin (CALM), and glycogen debranching enzyme (AGL). These interactions are essential for the regulation and breakdown of glycogen (MigockaPatrzałek2021Muscle). PYGM also interacts with RAC1, a kinase that modulates its enzymatic activity, influencing T-cell migration and proliferation (MigockaPatrzałek2021Muscle).

In muscle cells, PYGM interacts with the long non-coding RNA Linc-RAM, which regulates its enzymatic activity. This interaction is crucial for muscle cell differentiation, as Linc-RAM enhances PYGM activity, promoting the differentiation process (Zhai2022LincRAM). The interaction between Linc-RAM and PYGM is direct and specific, as demonstrated by RNA immunoprecipitation and electrophoretic mobility shift assays (Zhai2022LincRAM).

PYGM also forms interactions with desmin, an intermediate filament protein, in muscle fibers. This interaction is observed in cases of glycogen storage disease caused by PYGM mutations, where desmin and myophosphorylase co-localize in aggregated structures, potentially contributing to muscle weakness (Echaniz‐Laguna2020A).


## References


[1. (MigockaPatrzałek2021Muscle) Marta Migocka-Patrzałek and Magdalena Elias. Muscle glycogen phosphorylase and its functional partners in health and disease. Cells, 10(4):883, April 2021. URL: http://dx.doi.org/10.3390/cells10040883, doi:10.3390/cells10040883. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells10040883)

[2. (Mamidi2019Pigment) Varun Mamidi, Indumathi E., Manikantan Shekar, Ramprasad Elumalai, Vamsi Krishna Makkena, Jaiju James Chakola, Varun Kumar Bandi, Niranjana Joy, and Jayakumar Matcha. Pigment nephropathy in a patient with pygm gene mutation. Kidney International Reports, 4(5):740–744, May 2019. URL: http://dx.doi.org/10.1016/j.ekir.2019.01.010, doi:10.1016/j.ekir.2019.01.010. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ekir.2019.01.010)

[3. (Zhai2022LincRAM) Lili Zhai, Xin Wan, Rimao Wu, Xiaohua Yu, Hu Li, Ran Zhong, Dahai Zhu, and Yong Zhang. Linc-ram promotes muscle cell differentiation via regulating glycogen phosphorylase activity. Cell Regeneration, March 2022. URL: http://dx.doi.org/10.1186/s13619-022-00109-8, doi:10.1186/s13619-022-00109-8. This article has 5 citations.](https://doi.org/10.1186/s13619-022-00109-8)

[4. (VillarrealSalazar2021Preclinical) Mónica Villarreal-Salazar, Astrid Brull, Gisela Nogales-Gadea, Antoni L. Andreu, Miguel A. Martín, Joaquín Arenas, Alfredo Santalla, Alejandro Lucia, John Vissing, Thomas O. Krag, and Tomàs Pinós. Preclinical research in mcardle disease: a review of research models and therapeutic strategies. Genes, 13(1):74, December 2021. URL: http://dx.doi.org/10.3390/genes13010074, doi:10.3390/genes13010074. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes13010074)

[5. (Quinlivan2010McArdle) R. Quinlivan, J. Buckley, M. James, A. Twist, S. Ball, M. Duno, J. Vissing, C. Bruno, D. Cassandrini, M. Roberts, J. Winer, M. Rose, and C. Sewry. Mcardle disease: a clinical review. Journal of Neurology, Neurosurgery &amp; Psychiatry, 81(11):1182–1188, September 2010. URL: http://dx.doi.org/10.1136/jnnp.2009.195040, doi:10.1136/jnnp.2009.195040. This article has 130 citations.](https://doi.org/10.1136/jnnp.2009.195040)

[6. (Santalla2017Genotypic) Alfredo Santalla, Gisela Nogales-Gadea, Alberto Blázquez Encinar, Irene Vieitez, Adrian González-Quintana, Pablo Serrano-Lorenzo, Inés García Consuegra, Sara Asensio, Alfonsina Ballester-Lopez, Guillem Pintos-Morell, Jaume Coll-Cantí, Helios Pareja-Galeano, Jorge Díez-Bermejo, Margarita Pérez, Antoni L. Andreu, Tomàs Pinós, Joaquín Arenas, Miguel A. Martín, and Alejandro Lucia. Genotypic and phenotypic features of all spanish patients with mcardle disease: a 2016 update. BMC Genomics, November 2017. URL: http://dx.doi.org/10.1186/s12864-017-4188-2, doi:10.1186/s12864-017-4188-2. This article has 52 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12864-017-4188-2)

[7. (Echaniz‐Laguna2020A) Andoni Echaniz‐Laguna, Xavière Lornage, Pascal Laforêt, Mette C. Orngreen, Evelina Edelweiss, Guy Brochier, Mai T. Bui, Roberto Silva‐Rojas, Catherine Birck, Béatrice Lannes, Norma B. Romero, John Vissing, Jocelyn Laporte, and Johann Böhm. A new glycogen storage disease caused by a dominant <scp>pygm</scp> mutation. Annals of Neurology, 88(2):274–282, June 2020. URL: http://dx.doi.org/10.1002/ana.25771, doi:10.1002/ana.25771. This article has 6 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.25771)